

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use REVTORPYK safely and effectively. See full prescribing information for REVTORPYK.

REVTORPYK (gedatolisib) for Injection, for intravenous infusion
Initial U.S. Approval: 2026

INDICATIONS AND USAGE

REVTORPYK is a kinase inhibitor indicated in combination with fulvestrant, with or without palbociclib, for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a *PIK3CA* mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. (1)

DOSAGE AND ADMINISTRATION

- **Recommended dosage:** 180 mg intravenously as a 30-minute infusion once weekly on Days 1, 8, and 15 of a 28-day cycle (2.2)
- Prophylactically initiate steroid-containing alcohol-free mouthwash to reduce the incidence and severity of stomatitis. (2.3)
- See Full Prescribing Information for dosage modifications due to adverse reactions. (2.4)
- See Full Prescribing Information for instructions on preparation and administration. (2.5)

DOSAGE FORMS AND STRENGTHS

For Injection: 180 mg gedatolisib in a lyophilized powder in a single-dose vial. (3)

CONTRAINDICATIONS

None. (4)

WARNINGS AND PRECAUTIONS

- **Stomatitis:** REVTORPYK can cause severe stomatitis, including mouth ulcers. Initiate steroid-containing alcohol-free mouthwash prior to starting treatment. Withhold, reduce dose, or permanently discontinue REVTORPYK based on severity. (2.3, 2.4, 5.1)
- **Dermatologic Adverse Reactions:** REVTORPYK can cause severe rash. Monitor patients for rash and infectious sequelae. Instruct patients to limit sun exposure during REVTORPYK treatment.

Withhold, reduce dose, or permanently discontinue REVTORPYK based on severity. (2.4, 5.2)

- **Hyperglycemia:** REVTORPYK can cause severe hyperglycemia. Evaluate blood glucose levels and hemoglobin A1c prior to starting and at regular intervals during treatment. Withhold, reduce dose, or permanently discontinue REVTORPYK based on severity. (2.4, 5.3)
- **Embryo-Fetal Toxicity:** REVTORPYK can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception. Refer to the Prescribing Information of palbociclib and fulvestrant for pregnancy and contraception information. (5.4, 8.1, 8.3)

ADVERSE REACTIONS

- The most common ($\geq 20\%$) adverse reactions, including laboratory abnormalities when given in combination with fulvestrant and palbociclib were decreased white blood cells, decreased neutrophils, decreased hemoglobin, decreased lymphocytes, stomatitis, nausea, decreased platelets, increased fasting glucose, fatigue, vomiting, rash, constipation, diarrhea, increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), musculoskeletal pain, decreased sodium, and increased eosinophils. (6.1)
- The most common ($\geq 20\%$) adverse reactions, including laboratory abnormalities when given in combination with fulvestrant were stomatitis, increased fasting glucose, increased eosinophils, decreased hemoglobin, nausea, rash, increased ALT, fatigue, musculoskeletal pain, decreased lymphocytes, vomiting, increased AST, pruritus, and diarrhea. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Celcuity Inc. at 1-877-4-CELCUITY (1-877-423-5284) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

USE IN SPECIFIC POPULATIONS

Lactation: Advise not to breastfeed. (8.2)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 7/2026

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

- 2.1 Patient Selection
- 2.2 Recommended Dosage and Administration
- 2.3 Stomatitis Prophylaxis
- 2.4 Dosage Modification for Adverse Reactions
- 2.5 Preparation and Administration

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Stomatitis
- 5.2 Dermatologic Adverse Reactions
- 5.3 Hyperglycemia
- 5.4 Embryo-Fetal Toxicity

6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.3 Females and Males of Reproductive Potential

8.4 Pediatric Use

8.5 Geriatric Use

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

REVTORPYK is indicated in combination with fulvestrant, with or without palbociclib, for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a *PIK3CA* mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting [see *Dosage and Administration (2.1) and Clinical Studies (14)*].

2 DOSAGE AND ADMINISTRATION

2.1 Patient Selection

Select patients for treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer with REVTORPYK based on the absence of detected *PIK3CA* mutations in breast cancer [see *Clinical Studies (14)*]. An FDA-authorized test for the determination of *PIK3CA* mutation status in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer is not available.

2.2 Recommended Dosage and Administration

The recommended dosage of REVTORPYK is 180 mg as an intravenous infusion over 30 minutes once weekly on Days 1, 8, and 15 of every 28-day cycle, in combination with fulvestrant, with or without palbociclib, until disease progression or unacceptable toxicity.

If a planned dose is delayed or missed, administer as soon as possible thereafter. Do not wait until the next planned dose in the cycle. Adjust the timing of the subsequent dose to maintain the 3 weeks on followed by 1 week off schedule.

Refer to the Prescribing Information for fulvestrant and palbociclib administered in combination with REVTORPYK for additional dosing information.

2.3 Stomatitis Prophylaxis

Initiate steroid-containing alcohol-free mouthwash when starting REVTORPYK. Continue to administer steroid-containing alcohol-free mouthwash 4 times daily for the first 8 weeks of treatment and longer if needed [see *Warnings and Precautions (5.1) and Patient Counseling Information (17)*].

2.4 Dosage Modifications for Adverse Reactions

The recommended dosage reduction levels for adverse reactions are listed in Table 1.

Table 1: Recommended Dosage Reductions of REVTORPYK for Adverse Reactions

Dose Reductions	Recommended Dose
First	150 mg
Second	130 mg

Permanently discontinue REVTORPYK in patients who are unable to tolerate 130 mg intravenously once weekly on Days 1, 8, and 15 of every 28-day cycle.

The recommended dosage modifications for adverse reactions are described in Table 2.

Table 2: Recommended Dosage Modifications of REVTORPYK for Adverse Reactions

Adverse Reaction	Severity^a	Dosage Modification
Stomatitis <i>[see Warnings and Precautions (5.1)]</i>	Grade 3	- Withhold REVTORPYK until recovery to Grade ≤ 2. - Resume at next lower dose.
	Grade 4	Permanently discontinue REVTORPYK.
Hematologic Toxicities <i>[see Adverse Reactions (6.1)]</i>	Grade 4	- Withhold REVTORPYK until recovery to Grade ≤ 2. - Resume at next lower dose.
Dermatologic Adverse Reactions <i>[see Warnings and Precautions (5.2)]</i>	Grade 3 rash (both maculopapular and acneiform)	- Withhold REVTORPYK until recovery to Grade ≤ 1. - Resume at next lower dose. - For recurrent Grade 3, permanently discontinue REVTORPYK.
	Grade 4 rash (acneiform)	Permanently discontinue REVTORPYK.
	Any Grade of Stevens-Johnson Syndrome (SJS)/Toxic Epidermal Necrolysis (TEN) or other SJS/TEN-like severe skin reactions	Permanently discontinue REVTORPYK.
Hyperglycemia (Fasting Glucose [FG]) <i>[see Warnings and Precautions (5.3)]</i>	FG levels (FPG or FBG) > ULN-160 mg/dL (>ULN-8.9 mmol/L)	- No adjustment of REVTORPYK required. - Initiate dietary modifications and ensure adequate hydration. - Consider initiating or intensifying oral anti-hyperglycemic treatment as clinically indicated.
	FG levels 161-250 mg/dL (9-13.9 mmol/L)	- No adjustment of REVTORPYK required. - Initiate dietary modifications, ensure adequate hydration, and consider initiation or intensify anti-hyperglycemic treatment. - Consider consultation with a healthcare professional experienced in the treatment of hyperglycemia.
	251-500 mg/dL (14-27.8 mmol/L)	- Ensure adequate hydration. - Retest glucose: - If glucose remains >250 mg/dL, initiate or intensify anti-hyperglycemic treatment and withhold REVTORPYK. - If glucose is <250 mg/dL (<13.9 mmol/L), initiate REVTORPYK at the same dose. - Consider consultation with a healthcare professional experienced in the treatment of hyperglycemia.

	>500 mg/dL (>27.8 mmol/L)	• Withhold REVTORPYK • Initiate or intensify anti-hyperglycemic treatment. • Ensure adequate hydration. • Consider consultation with a healthcare professional experienced in the treatment of hyperglycemia. • If glucose decreases to <250 mg/dL (<13.9 mmol/L), resume REVTORPYK at next lower dose. • For recurrent increase in glucose >500 mg/dL, permanently discontinue REVTORPYK.
Other Adverse Reactions [see Adverse Reactions (6.1)]	Grade 2	• If Grade 2 persists for longer than 3 weeks, withhold REVTORPYK until recovery to Grade ≤1, then resume treatment at next lower dose.
	Grade 3	• Withhold REVTORPYK until recovery to Grade ≤1. • Resume at next lower dose.
	Grade 4	• Permanently discontinue REVTORPYK.

Abbreviations: FBG, fasting blood glucose; FPG, fasting plasma glucose; ULN, upper limit of normal.

^a Adverse reactions graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.

2.5 Preparation and Administration

Reconstitute and further dilute REVTORPYK prior to intravenous infusion. Use appropriate aseptic technique.

Reconstitution

- Add 20 mL of Sterile Water for Injection or 5% Dextrose Injection to the REVTORPYK vial.
- Swirl the vial until completely dissolved for up to 5 minutes. Minor foaming and opalescence may be observed.
- If not used immediately, store the reconstituted solution in the vial for up to 4 hours at room temperature at 20°C to 25°C (68°F to 77°F). Do not freeze or refrigerate.
- REVTORPYK does not contain a preservative. Discard unused reconstituted REVTORPYK vial after 4 hours.
- **DO NOT** use common chloride-containing infusion solutions (for example: normal saline, Ringer's solution, Lactated Ringer's solution).

Dilution

- Withdraw the appropriate volume of the reconstituted solution from the REVTORPYK vial (See Table 3) using a sterile syringe. Inspect visually for particulate matter and discoloration prior to administration. The solution should be free of visible particulates, be clear (minor opalescence is acceptable) and colorless to pale yellow. Discard the vial if particles or discoloration are observed.

Table 3: Volume to Withdraw from Reconstituted Vial Based on Dose

Dose	Volume of Reconstituted REVTORPYK
180 mg	20 mL
150 mg	17 mL
130 mg	14 mL

- Dilute the reconstituted REVTORPYK in an infusion bag containing 250 mL of 5% Dextrose Injection.
- Gently invert the infusion bag to thoroughly mix the solution. Do not shake.
- If not used immediately, store the diluted REVTORPYK infusion solution at room temperature at 20°C to 25°C (68°F to 77°F) for up to 24 hours. Do not freeze or refrigerate.
- Discard any unused portion left in the vial.

Administration

- Flush the intravenous line with 5% Dextrose Injection before REVTORPYK administration.
- Administer REVTORPYK by intravenous infusion over 30 minutes through a dedicated infusion line equipped with a sterile, non-pyrogenic, in-line or add-on polyether sulfone filter (0.2- or 0.22-micron pore size) and catheter.
 - **DO NOT** administer any chloride-containing solutions (e.g., Sodium Chloride for Injection, Ringer's Injection, Lactated Ringer's Injection) or other medications concomitantly via the same intravenous line.
- Upon completion of the infusion, flush the intravenous line with 5% Dextrose Injection.
- Discard any unused portions left in the infusion set.

3 DOSAGE FORMS AND STRENGTHS

REVTORPYK is supplied as a sterile, white to off-white lyophilized powder for injection containing 180 mg gedatolisib in a single-dose vial for reconstitution and further dilution.

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Stomatitis

REVTORPYK can cause severe stomatitis, including ulcers and oral mucositis.

In Study 1 of VIKTORIA-1, stomatitis occurred in 72% of patients treated with REVTORPYK with fulvestrant and palbociclib, including Grade 3 events in 22% of patients. Prophylactic steroid-containing alcohol-free mouthwash was required for a minimum of 8 weeks. The median time to onset was 7 days (range: 1 to 457 days). Stomatitis led to REVTORPYK dose reduction in 19% and permanent discontinuation in 3.8% of patients. Stomatitis occurred in 58% of patients treated with REVTORPYK with fulvestrant, including Grade 3 events in 12% of patients. The median time to onset was 4 days (range: 1 to 524 days). Stomatitis led to REVTORPYK dose reduction in 9% and permanent discontinuation in 1.5% of patients.

Prophylactically initiate steroid-containing alcohol-free mouthwash to reduce the incidence and severity of stomatitis [see *Dosage and Administration* (2.3)].

If stomatitis occurs, increase the frequency of mouthwash and administer other topical treatments as clinically indicated. Withhold, reduce dose, or permanently discontinue REVTORPYK based on severity [see *Dosage and Administration* (2.4)].

5.2 Dermatologic Adverse Reactions

REVTORPYK can cause severe rash.

In Study 1 of VIKTORIA-1, rash occurred in 30% of patients treated with REVTORPYK in combination with fulvestrant and palbociclib, including Grade 3 events in 6% of patients. The median time to onset was 21 days (range: 3 to 260 days) after starting REVTORPYK. Rash led to REVTORPYK dose reduction in 5% and permanent discontinuation in 0.8% of patients. Rash occurred in 40% of patients treated with REVTORPYK in

combination with fulvestrant, including Grade 3 events in 5% of patients. Rash led to REVTORPYK dose reduction in 6% and permanent discontinuation in 0.8% of patients. The median time to onset was 31.5 days (range: 2 to 407 days) after starting REVTORPYK.

Monitor patients receiving REVTORPYK for rash and infectious sequelae. Instruct patients to limit sun exposure during REVTORPYK treatment.

Withhold, reduce dose, or permanently discontinue REVTORPYK based on severity [*see Dosage and Administration (2.4)*].

5.3 Hyperglycemia

Severe hyperglycemia can occur in patients treated with REVTORPYK. Hyperglycemia is associated with drugs that inhibit the PI3K/AKT/mTOR pathway.

In Study 1 of VIKTORIA-1, increased fasting glucose (FG) from baseline occurred in 46% of patients treated with REVTORPYK in combination with fulvestrant and palbociclib, including Grade 1 (FG >ULN to 160 mg/dL) in 36% of patients, Grade 2 (FG >160 to 250 mg/dL) in 8% of patients and Grade 3 (FG >250 to 500 mg/dL) in 0.9% of patients. Increased fasting glucose from baseline occurred in 57% of patients treated with REVTORPYK in combination with fulvestrant, including Grade 1 in 44% of patients, Grade 2 in 11% of patients and Grade 3 in 1.8% of patients.

The safety of REVTORPYK in patients with Type 1 or uncontrolled Type 2 diabetes mellitus has not been established as these patients were excluded from Study 1 of VIKTORIA-1 [*see Clinical Studies (14)*].

Before initiating treatment with REVTORPYK, test fasting glucose levels (FPG or FBG), HbA1c levels, and optimize fasting glucose. Achieve optimal glucose control before starting each REVTORPYK infusion [*see Dosage and Administration (2.4)*]. Manage hyperglycemia with anti-hyperglycemic medications. Patients with a history of well-controlled Type 2 diabetes mellitus may require intensified anti-hyperglycemic treatment and close monitoring of FG levels. Consider consultation with a healthcare professional experienced in the treatment of hyperglycemia. Initiate at-home glucose monitoring for patients with HbA1c level >6.4%. Advise patients of the signs and symptoms of hyperglycemia and counsel patients on lifestyle changes.

Withhold, reduce dose, or permanently discontinue REVTORPYK based on severity [*see Dosage and Administration (2.4)*].

5.4 Embryo-Fetal Toxicity

Based on its mechanism of action, REVTORPYK can cause fetal harm when administered to a pregnant woman [*see Clinical Pharmacology (12.1)*]. Inhibition of PI3K and mTOR pathways have been associated with adverse embryo-fetal growth and lethality in animals.

Advise patients of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with REVTORPYK and for 2 weeks after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with REVTORPYK and for 2 weeks after the last dose [*see Use in Specific Populations (8.1, 8.3)*].

REVTORPYK is used in combination with fulvestrant, with or without palbociclib. Refer to the Prescribing Information of fulvestrant and palbociclib for pregnancy and contraception information. When REVTORPYK is used in combination, advise patients to use effective contraception during treatment and for the longest post-treatment duration recommended in the Prescribing Information of any of the individual products.

6 ADVERSE REACTIONS

The following clinically significant adverse reactions are described elsewhere in the labeling:

- Stomatitis [*see Warnings and Precautions (5.1)*]

- Dermatologic adverse reactions [see *Warnings and Precautions* (5.2)]
- Hyperglycemia [see *Warnings and Precautions* (5.3)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of REVTORPYK was evaluated in 383 adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer without a detectable *PIK3CA* mutation in Study 1 of VIKTORIA-1 [see *Clinical Studies* (14)].

Patients received either Arm A: REVTORPYK 180 mg intravenously once weekly for 3 weeks on followed by 1 week off (Days 1, 8, 15 for each 28-day cycle) in combination with fulvestrant 500 mg intramuscularly on cycle 1 Days 1 and 15, and then at Day 1 of each subsequent 28-day cycle and palbociclib 125 mg orally once daily for 21 days followed by 7 days off treatment for each 28-day cycle (n = 130); or Arm B: REVTORPYK in combination with fulvestrant (n = 130); or Arm C: fulvestrant alone (n = 123). The dose, route of administration, and frequency of each drug in Arms B and C were the same as Arm A. The median duration of exposure for REVTORPYK plus fulvestrant and palbociclib was 6.2 months (range: 0.5 to 25 months) and 5.7 months (range: 0 to 26 months) for REVTORPYK plus fulvestrant.

REVTORPYK in Combination with Fulvestrant and Palbociclib

Serious adverse reactions occurred in 25% of patients who received REVTORPYK in combination with fulvestrant and palbociclib. Serious adverse reactions in $\geq 1\%$ of patients included pneumonia (3.8%), thrombosis (3.8%), and stomatitis (1.5%). Fatal adverse reactions occurred in 2.3% of patients who received REVTORPYK in combination with fulvestrant and palbociclib, including (0.8% each) pneumonia, multiorgan failure, and hepatic failure.

Permanent discontinuation of REVTORPYK due to an adverse reaction occurred in 12% of patients receiving REVTORPYK in combination with fulvestrant and palbociclib. Adverse reactions that resulted in permanent discontinuation of REVTORPYK were stomatitis, nausea, rash, pneumonitis, diplopia, hypertension, vomiting, breast ulceration, and squamous cell carcinoma of the lung.

Dosage interruptions of REVTORPYK due to an adverse reaction occurred in 64% of patients receiving REVTORPYK in combination with fulvestrant and palbociclib. Adverse reactions which required dosage interruption of REVTORPYK in $\geq 2\%$ of patients included neutropenia, stomatitis, decreased neutrophil count, fatigue, anemia, leukopenia, increased aspartate aminotransferase (AST), increased alanine aminotransferase (ALT), pyrexia, rash, thrombosis, pneumonia, diarrhea, hyperglycemia, thrombocytopenia, upper respiratory tract infection, pruritus, and urinary tract infection.

Dose reductions of REVTORPYK due to an adverse reaction occurred in 41% of patients receiving REVTORPYK in combination with fulvestrant and palbociclib. Adverse reactions which required dose reduction of REVTORPYK in $\geq 2\%$ of patients included stomatitis, neutropenia, rash, nausea, increased AST, and increased ALT.

The most common ($\geq 20\%$) adverse reactions, including laboratory abnormalities, in the REVTORPYK in combination with fulvestrant and palbociclib arm were decreased white blood cell, decreased neutrophils, decreased hemoglobin, decreased lymphocytes, stomatitis, nausea, decreased platelets, increased fasting glucose, fatigue, vomiting, rash, constipation, diarrhea, increased ALT, increased AST, musculoskeletal pain, decreased sodium, and increased eosinophils.

REVTORPYK in Combination with Fulvestrant

Serious adverse reactions occurred in 19% of patients who received REVTORPYK in combination with

fulvestrant. Serious adverse reactions in $\geq 1\%$ of patients included pneumonia (3.8%), thrombosis (2.3%), pleural effusion (1.5%), and pneumonitis (1.5%). Fatal adverse reactions occurred in 2.3% of patients who received REVTORPYK in combination with fulvestrant, including (0.8% each) acute respiratory failure, bronchopulmonary hemorrhage, and cardiac arrest.

Permanent discontinuation of REVTORPYK due to an adverse reaction occurred in 9% of patients receiving REVTORPYK in combination with fulvestrant. Adverse reactions that resulted in permanent discontinuation of REVTORPYK were stomatitis, nausea, rash, pneumonitis, acute respiratory failure, myocarditis, angina pectoris, fatigue, infusion-related reaction, peripheral neuropathy, and oral pain.

Dosage interruptions of REVTORPYK due to an adverse reaction occurred in 37% of patients receiving REVTORPYK in combination with fulvestrant. Adverse reactions which required dosage interruption of REVTORPYK in $\geq 2\%$ of patients included fatigue, increased AST, increased ALT, stomatitis, pneumonia, pyrexia, and diarrhea.

Dose reductions of REVTORPYK due to an adverse reaction occurred in 22% of patients receiving REVTORPYK in combination with fulvestrant. Adverse reactions which required dose reduction of REVTORPYK in $\geq 2\%$ of patients included stomatitis, rash, and nausea.

The most common ($\geq 20\%$) adverse reactions, including laboratory abnormalities, in the REVTORPYK in combination with fulvestrant arm were stomatitis, increased fasting glucose, increased eosinophils, decreased hemoglobin, nausea, rash, increased ALT, fatigue, musculoskeletal pain, decreased lymphocytes, vomiting, increased AST, pruritus, and diarrhea.

Tables 4 and 5 summarize the adverse reactions and laboratory abnormalities in Study 1 of VIKTORIA-1, respectively.

Table 4: Adverse Reactions ($\geq 10\%$) in Patients Who Received REVTORPYK plus Fulvestrant and Palbociclib in Study 1 of VIKTORIA-1

Adverse Reaction	REVTORPYK + Fulvestrant + Palbociclib (N=130)		REVTORPYK + Fulvestrant (N=130)		Fulvestrant (N=123)	
	All Grades	Grade 3 or 4 ^b	All Grades	Grade 3 or 4 ^b	All Grades	Grade 3 or 4 ^b
	%	%	%	%	%	%
Gastrointestinal Disorders						
Stomatitis ^a	72	22	58	12	2.4	0
Nausea	51	3.8	44	0.8	13	0.8
Vomiting	35	1.5	24	0	4.1	0
Diarrhea ^a	26	1.5	20	1.5	4.9	0
Constipation	26	0	16	0	3.3	0
Abdominal pain ^a	13	0	9	0	8	4.1
General Disorders and Administration Site Conditions						
Fatigue ^a	43	2.3	34	0.8	13	0.8
Pyrexia	14	0	10	0	1.6	0
Mucosal dryness ^a	11	0	10	0	1.6	0
Skin and Subcutaneous Tissue Disorders						
Rash ^a	30	6	40	5	0	0

Pruritus	19	0.8	22	0	1.6	0
Musculoskeletal and Connective Tissue Disorders						
Musculoskeletal pain ^a	24	0.8	26	3.1	24	2.4
Nervous System Disorders						
Dysgeusia ^a	19	0	17	0	0.8	0
Dizziness ^a	10	0	9	0	3.3	0
Metabolism and nutrition disorder						
Decreased appetite	19	0.8	11	0.8	4.1	0.8
Infections and Infestations						
Urinary Tract Infection ^a	13	0	15	0	4.1	0
Respiratory, Thoracic and Mediastinal Disorders						
Cough ^a	11	0	18	0	7	0
Vascular Disorders						
Thrombosis ^a	10	3.1	3.1	2.3	0	0

Grading according to CTCAE 5.0.

N=number of patients.

^a Includes multiple related terms.

^b No Grade 4 events were reported.

Table 5: Select Laboratory Abnormalities (≥10%) in Patients Who Received REVTORPYK plus Fulvestrant and Palbociclib in Study 1 of VIKTORIA-1

Laboratory Abnormality	REVTORPYK + Fulvestrant + Palbociclib (N=130)		REVTORPYK + Fulvestrant (N=130)		Fulvestrant (N=123)	
	All Grades	Grade 3 or 4	All Grades	Grade 3 or 4	All Grades	Grade 3 or 4
	%	%	%	%	%	%
Hematology						
WBC decreased	93	45	16	0.8 ^b	13	0.8 ^b
Neutrophils decreased	85	65	14	1.6	10	0.8 ^b
Hemoglobin decreased	84	12 ^b	46	0.8 ^b	19	2.5 ^b
Lymphocytes decreased	73	27	25	2.6 ^b	21	5.4 ^b
Platelets decreased	49	6	5	0.8	11	0.8
Eosinophils increased	20	0	53	0	11	0
Chemistry						
Glucose (fasting) increased ^a	46	0.9 ^b	57	1.8 ^b	17	0
ALT increased	25	0.8 ^b	35	2.3	21	0
AST increased	24	2.4	23	3.1 ^b	18	1.7 ^b

Sodium decreased	21	1.6 ^b	16	0.8 ^b	13	1.7
Magnesium decreased	19	0	16	0	3.4	0
Potassium decreased	19	1.6 ^b	14	1.6 ^b	9	1.7 ^b
Glucose decreased	17	3.1	9	1.5	2.6	0.9
CPK increased	15	0.9 ^b	12	2.5	11	0.9
Creatinine increased	14	0.8 ^b	10	1.6	8	0.8 ^b
Serum amylase increased	14	0.8 ^b	10	2.3	9	0
ALP increased	12	0	18	0	21	1.7 ^b
Potassium increased	10	0.8 ^b	5	0	8	0.8 ^b

N=number of patients; WBC = white blood cells; AST = aspartate aminotransferase; ALT = alanine aminotransferase; CPK = creatine phosphokinase; ALP = alkaline phosphatase.

^a Glucose results were graded per CTCAE v4.03.

^b No Grade 4 events were reported.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

REVTORPYK is used in combination with fulvestrant, with or without palbociclib. Refer to the Prescribing Information for fulvestrant and palbociclib for pregnancy information. When used in combination with REVTORPYK, advise patients to use effective contraception during treatment and for the longest post-treatment duration recommended in the Prescribing Information of any of the individual products.

Based on its mechanism of action, REVTORPYK can cause fetal harm when administered to a pregnant woman [see *Clinical Pharmacology (12.1)*]. There are no available data in pregnant women to inform the drug-associated risk. Animal reproductive toxicity studies have not been conducted with REVTORPYK. Inhibition of PI3K and mTOR pathways have been associated with adverse embryo-fetal growth and lethality in animals (*see Data*).

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data

Animal Data

PIK3CA knockout mice experienced developmental delay at embryonic day 9.5 and mortality between embryonic day 9.5 and 10.5. *mTOR* knockout mice experienced early lethality by embryonic day 7.5. In both animal models, early embryonic death was a result of impaired cell proliferation and structural development.

8.2 Lactation

Risk Summary

REVTORPYK is used in combination with fulvestrant, with or without palbociclib. Refer to the Prescribing Information for fulvestrant and palbociclib for lactation information. When used in combination with REVTORPYK, advise patients to not breastfeed during treatment and for the longest post-treatment duration recommended in the Prescribing Information of any of the individual products.

There are no data on the presence of gedatolisib or its metabolites in human milk, its effects on milk production, or a breastfed child. Because of the potential for serious adverse reactions in a breastfed child, advise lactating women to not breastfeed during treatment with REVTORPYK and for 2 weeks after the last dose.

8.3 Females and Males of Reproductive Potential

REVTORPYK is used in combination with fulvestrant, with or without palbociclib. Refer to the Prescribing Information for fulvestrant and palbociclib for contraception and infertility information. When used in combination with REVTORPYK, advise patients to use effective contraception during treatment and for the longest post-treatment duration recommended in the Prescribing Information of any of the individual products.

Based on its mechanism of action, REVTORPYK can cause fetal harm when administered to a pregnant woman [see *Use in Specific Populations* (8.1)].

Pregnancy Testing

Verify the pregnancy status of females of reproductive potential prior to initiating treatment with REVTORPYK.

Contraception

Females

Advise females of reproductive potential to use effective contraception during treatment with REVTORPYK and for 2 weeks after the last dose.

Males

Advise male patients with female partners of reproductive potential to use effective contraception during treatment with REVTORPYK and for 2 weeks after the last dose.

Infertility

Based on animal studies, REVTORPYK may impair fertility in females and males of reproductive potential. Findings in animals were reversible [see *Nonclinical Toxicology* (13.1)].

8.4 Pediatric Use

The safety and efficacy of REVTORPYK in pediatric patients have not been established.


8.5 Geriatric Use

Of 260 patients who received REVTORPYK, 55 patients (21%) were ≥ 65 and < 75 years of age and 17 patients (6.5%) were ≥ 75 years of age [see *Clinical Studies* (14)].

In patients treated with REVTORPYK in combination with fulvestrant and palbociclib, the incidence of Grade ≥ 3 stomatitis and rash was higher in patients ≥ 65 years of age (37% and 11%, respectively) compared to younger patients (16% and 4.3%, respectively). In patients treated with REVTORPYK in combination with fulvestrant, the incidence of Grade ≥ 3 stomatitis and rash was higher in patients ≥ 65 years of age (18% and 12%, respectively) compared to younger patients (10% and 3.1%, respectively). No overall differences in effectiveness of REVTORPYK were observed between patients ≥ 65 years of age and younger patients.

11 DESCRIPTION

REVTORPYK for injection contains gedatolisib, a kinase inhibitor. The chemical name of gedatolisib is 1-[4-(4-dimethylaminopiperidine-1-carbonyl)phenyl]-3-[4-(4,6-dimorpholin-4-yl-[1,3,5]triazin-2-yl)phenyl]urea. The molecular formula for gedatolisib is $C_{32}H_{41}N_9O_4$ and the molecular weight is 615.74 g/mol. Gedatolisib is a white to off-white crystalline solid that is insoluble in water. The chemical structure of gedatolisib is shown below:



REVTORPYK for injection is a sterile, preservative-free, lyophilized white to off-white cake or powder with cake supplied in a single-dose vial. Each vial delivers 180 mg of gedatolisib. The lyophilized powder also contains 720 mg of hydroxypropyl β cyclodextrin and 48.6 mg of lactic acid and may include hydrochloric acid and/or sodium hydroxide for pH adjustment.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Gedatolisib is a kinase inhibitor of class I PI3K isoforms (α , β , δ , γ) and mTOR complexes mTORC1 and mTORC2, resulting in downstream inhibition of multiple effectors, including AKT. In estrogen receptor (ER)-positive breast cancer cell lines and xenograft models harboring wild-type or mutant *PIK3CA*, gedatolisib induced apoptosis and anti-proliferative effects in vitro and reduced tumor cell growth in vivo. In a human ER-positive breast cancer xenograft model harboring a *PIK3CA* mutation, the combination of gedatolisib with palbociclib and fulvestrant increased tumor growth inhibition compared to each treatment alone or the doublet combinations.

12.2 Pharmacodynamics

Exposure-Response Relationships

The exposure-response relationship and time course of pharmacodynamic response for the effectiveness of gedatolisib have not been fully characterized. An increased incidence of stomatitis or mucositis (Grade 3 and 4), nausea, vomiting, hyperglycemia, and adverse reaction leading to dosage modification or discontinuation was observed with higher gedatolisib exposure at the dose range of 10 mg to 319 mg (0.06 to 1.8 times the approved recommended dose).

Cardiac Electrophysiology

At weekly doses up to 319 mg (1.8 times the recommended dose), clinically significant QTc interval prolongation was not observed.

12.3 Pharmacokinetics

Gedatolisib pharmacokinetic parameters were observed at the approved recommended dosage in patients with breast cancer and are presented as mean (% coefficient of variation [%CV]), unless otherwise specified. Gedatolisib maximum plasma concentration ($C_{\max}$) is 13,700 (29%) ng/mL and area under the curve (AUC) is 21,400 (21%) ng·h/mL. Gedatolisib $C_{\max}$ and AUC values increase dose proportionally in the dose range 10 mg to 319 mg (0.06 to 1.8 times the recommended dose). No accumulation of gedatolisib is observed after once-weekly administration.

Distribution

Gedatolisib plasma protein binding is 98%, and is not concentration dependent, in vitro. Gedatolisib blood-to-plasma ratio is 0.87, in vitro. Gedatolisib volume of distribution is 393 L.

Elimination

Gedatolisib elimination half-life ($t_{1/2}$) is 36 hours with an estimated clearance of 8 (23%) L/hour.

Excretion

After a single dose of radiolabeled gedatolisib 89 mg to healthy subjects, approximately 67.4% of the dose was recovered in feces (67% unchanged) and 12.2% in urine (11.6% unchanged).

Specific Populations

No clinically significant effects on the pharmacokinetics of gedatolisib were observed based on age (21 to 84 years), sex, race (White [78%], Asian [9.1%], Black or African American [4.1%]) body weight (35 to 168 kg), mild hepatic impairment (total bilirubin $\leq 1.5 \times$ ULN and any AST) or estimated glomerular filtration rate (eGFR) ≥ 45 mL/min/1.73 m² (MDRD equation). The effect of moderate (total bilirubin >1.5 to 3 times ULN with any AST) or severe (total bilirubin $>3 \times$ ULN with any AST) hepatic impairment, eGFR <45 mL/min/1.73 m², or dialysis on gedatolisib pharmacokinetics is unknown.

Drug Interactions

Clinical Studies and Model-Informed Approaches

No clinically significant differences in the pharmacokinetics of the following drugs were observed when used concomitantly with gedatolisib: metformin (MATE1, MATE2-K, and OCT1 substrate), rosuvastatin (BCRP substrate), or repaglinide (CYP2C8 sensitive substrate).

In Vitro Studies

CYP450 Enzymes: Gedatolisib is not an inhibitor of CYP1A2, CYP2A6, or CYP2B6.

The ability of gedatolisib to induce CYP450 enzymes is unknown given the results of the vitro studies were inconclusive due to decreased viability of hepatocytes.

Transporter Systems: Gedatolisib is a substrate of P-gp and BCRP and is not a substrate for OATP1B1, OATP1B3, OCT1, NTCP, MRP2, or MRP3.

Gedatolisib did not inhibit P-gp, OATP1B1, OATP1B3, OAT1, OAT3, OCT2, and BSEP.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

Carcinogenicity studies have not been conducted with gedatolisib.

Mutagenesis

Gedatolisib was not mutagenic in vitro in a bacterial reverse mutation (Ames) assay and was not clastogenic in an in vitro human lymphocyte chromosomal aberration assay. Gedatolisib was not genotoxic in an in vivo rat bone marrow micronucleus assay.

Impairment of Fertility

Fertility studies with gedatolisib have not been conducted. In repeated-dose toxicity studies, gedatolisib was administered intravenously once weekly on a 3 weeks on/1 week off schedule for 3 months in rats and dogs. Degeneration/atrophy of seminiferous tubules in testes was observed in male rats and dogs at ≥ 5 mg/kg and 0.5 mg/kg, respectively, and atrophy of prostate was observed in male rats at ≥ 1 mg/kg. In female rats, atrophy in the vagina and uterus was observed at ≥ 5 mg/kg. All findings occurred at exposures ≤ 0.2 times the human AUC at the recommended dose. Findings in males and females were reversible following a 12-week recovery period.

14 CLINICAL STUDIES

The efficacy of REVTORPYK in combination with fulvestrant, with or without palbociclib, was evaluated in Study 1 of VIKTORIA-1 (NCT05501886), an open label, randomized, multicenter clinical trial that enrolled 392 adult patients with locally advanced (inoperable) or metastatic HR-positive, HER2-negative (defined as immunohistochemistry (IHC) 0 or 1+, or IHC 2+/in situ hybridization (ISH-)) breast cancer without a detectable *PIK3CA* mutation. The *PIK3CA* status was assessed centrally for the following *PIK3CA* mutations: C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, H1047L, H1047R, and H1047Y.

All patients were required to have progression on or after treatment with a CDK4/6 inhibitor and a non-steroidal aromatase inhibitor (AI) therapy. Patients could have received up to two prior lines of endocrine therapy for locally advanced (inoperable) or metastatic disease. Patients were excluded from the trial if they had Type 1 or uncontrolled Type 2 diabetes mellitus (requiring systemic insulin therapy), HbA1c >6.4%, and prior treatment with a PI3K inhibitor, AKT inhibitor, or mTOR inhibitor.

Patients were randomized (1:1:1) to three arms as follows:

- Arm A (N=131): REVTORPYK 180 mg intravenously once weekly for 3 weeks on followed by 1 week off (Days 1, 8, 15 for each 28-day cycle) in combination with fulvestrant 500 mg intramuscularly on cycle 1 Days 1 and 15, and then at Day 1 of each subsequent 28-day cycle, and palbociclib 125 mg orally once daily for 21 days followed by 7 days off treatment for each 28-day cycle (G+F+P), or
- Arm B (N=130): REVTORPYK 180 mg intravenously once weekly for 3 weeks on followed by 1 week off (Days 1, 8, 15 for each 28-day cycle) in combination with fulvestrant 500 mg intramuscularly on cycle 1 Days 1 and 15, and then at Day 1 of each subsequent 28-day cycle (G+F), or
- Arm C (N=131): Fulvestrant 500 mg intramuscularly on cycle 1 Days 1 and 15, and then at Day 1 of each subsequent 28-day cycle (F).

In addition, all pre/perimenopausal women were required to receive a gonadotropin-releasing hormone (GnRH) agonist. Randomization was stratified by presence of visceral metastases (yes or no), duration on immediate prior therapy (≤6 months or >6 months) and geographical region (Region 1: US or Region 2: Rest of World). Patients received treatment until disease progression or unacceptable toxicity. Patients on Arm C had the option to cross over to study Arm A or Arm B at the time of disease progression.

The major efficacy outcome was comparison of progression-free survival (PFS) assessed by blinded independent central review between patients enrolled in Arm A (G+F+P) and Arm C (F), and between patients enrolled in Arm B (G+F) and Arm C (F) evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Additional efficacy outcome measures were overall survival (OS), objective response rate (ORR) and duration of response (DoR).

The baseline demographic and disease characteristics were: median age 56 years (range: 28 to 83 years); 99% female, of which 26% were pre/perimenopausal; 70% White, 16% Asian, 7% unknown, 2% Black or African American; 65% Not Hispanic/Latino, 28% Hispanic or Latino, 7% not reported/unknown; 100% had Stage IV breast cancer; all patients had prior endocrine therapy and prior CDK4/6 inhibitor therapy; 79% had visceral metastases; and Eastern Cooperative Oncology Group (ECOG) performance status of 0 (59%) or 1 (41%).

Efficacy results are summarized in Table 6 and Figures 1 and 2. At the time of the PFS analysis, OS data were not mature with 25% deaths in the overall population.

Table 6: Efficacy Results in Patients with Locally Advanced or Metastatic Breast Cancer in Study 1 of VIKTORIA-1

	REVTORPYK + Fulvestrant + Palbociclib N=131	REVTORPYK + Fulvestrant N=130	Fulvestrant N=131
Progression-Free Survival (PFS)			
Patients with events, n (%)	59 (45)	69 (53)	89 (68)
Median ^a , months (95% CI)	9.3 (7.2, 16.6)	7.4 (5.5, 9.9)	2.0 (1.8, 2.3)
Hazard ratio (95% CI) ^b	0.24 ^c (0.17, 0.35)	0.33 ^d (0.24, 0.48)	N/A
p-value	<0.0001 ^c	<0.0001 ^d	N/A
Objective Response Rate (ORR)			
Patients with measurable disease	124	113	105
Patients with CR or PR, n (%)	39 (32)	32 (28)	1 (1.0)
95% CI	23, 40	20, 38	0, 5
Duration of Response (DoR)			
Median ^a , months (95% CI)	17.5 (8.8, NE)	12.0 (8.1, NE)	NE (NE, NE)

CI = confidence interval; CR = complete response; PR = partial response, NE = not estimable

^aBased on Kaplan-Meier estimates.

^bStratified Cox regression model, confidence intervals for hazard ratio is based on the score test (D.Y. Lin 2016).

^cArm A (REVTORPYK plus fulvestrant and palbociclib) versus Arm C (fulvestrant).

^dArm B (REVTORPYK plus fulvestrant) versus Arm C (fulvestrant).

Figure 1: Kaplan-Meier Plot of Progression-Free Survival in Study 1 of VIKTORIA-1: REVTORPYK Plus Fulvestrant and Palbociclib versus Fulvestrant





Figure 2: Kaplan-Meier Plot of Progression-Free Survival in Study 1 of VIKTORIA-1: REVTORPYK Plus Fulvestrant versus Fulvestrant



16 HOW SUPPLIED/STORAGE AND HANDLING

How Supplied

REVTORPYK for injection is a white to off-white lyophilized powder supplied as:

Carton Content	NDC
One 180 mg single-dose vial	NDC 84577-751-01

Storage and Handling

Store at 20°C to 25°C (68°F to 77°F), excursions permitted 15°C to 30°C (59°F to 86°F). Store vial in original carton until time of reconstitution.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Stomatitis

Inform patients of the risk of stomatitis. Advise patients to contact their healthcare provider if they experience any symptoms (e.g., painful redness, swelling, or sores in the mouth). Inform patients to use steroid-containing mouthwash for prophylaxis and treatment of stomatitis. Instruct patients not to eat or drink for at least 1 hour after administration of the steroid-containing mouthwash [see *Warnings and Precautions* (5.1)].

Dermatologic Adverse Reactions

Inform patients of the risks of dermatologic adverse reactions, including rash. Advise patients to limit sun exposure during treatment. Advise patients to contact their healthcare provider immediately if they develop a new rash [see *Warnings and Precautions* (5.2)].

Hyperglycemia

Inform patients of the risks of hyperglycemia and the need for monitoring of fasting blood glucose and HbA1c periodically during treatment. Advise patients to contact their healthcare provider immediately for signs and

symptoms of hyperglycemia (e.g., excessive thirst, urinating more often, blurred vision, confusion, difficulty breathing, or increased appetite with weight loss) [*see Warnings and Precautions (5.3)*].

Embryo-Fetal Toxicity

- Inform pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy [*see Warnings and Precautions (5.4) and Use in Specific Populations (8.1)*].
- Advise females of reproductive potential to use effective contraception during treatment with REVTORPYK and for 2 weeks after the last dose [*see Use in Specific Populations (8.3)*].
- Advise male patients with female partners of reproductive potential to use effective contraception during treatment with REVTORPYK and for 2 weeks after the last dose [*see Use in Specific Populations (8.3)*].
- Refer to the Prescribing Information of palbociclib and fulvestrant for pregnancy and contraception information. When used in combination with REVTORPYK, advise patients to use effective contraception during treatment and for the longest post-treatment duration recommended in the Prescribing Information of any of the individual products.

Lactation

Advise women not to breastfeed during treatment with REVTORPYK and for 2 weeks after the last dose [*see Use in Specific Populations (8.2)*]. Refer to the Prescribing Information of palbociclib and fulvestrant for lactation information. When used in combination, advise patients not to breastfeed during treatment and for the longest post-treatment duration recommended in the Prescribing Information of any of the individual products.

Infertility

Advise females and males of reproductive potential that REVTORPYK may impair fertility [*see Use in Specific Populations (8.3)*]. Refer to the Prescribing Information of palbociclib and fulvestrant for infertility information.

This product's labeling may have been updated. For full prescribing information, please visit www.celcuity.com.

Manufactured for:
Celcuity Inc.
2800 Campus Dr, Suite 140
Minneapolis, MN 55441

PATIENT INFORMATION

REVTORPYK (rev-tor-pik)
(gedatolisib)
for intravenous infusion

Important: REVTORPYK is used with fulvestrant and may also be used with palbociclib. You should also read the Patient Information that comes with fulvestrant and palbociclib.

What is REVTORPYK?

REVTORPYK is a prescription medicine used in combination with the medicine fulvestrant, with or without the medicine palbociclib to treat adults who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that:

- has spread to nearby tissue or lymph nodes (locally advanced) or that has spread to other parts of the body (metastatic), without an abnormal “*PIK3CA*” gene and
- whose cancer has come back and has spread to other parts of the body on or after at least 1 treatment with hormone (endocrine) therapy for metastatic disease.

Your healthcare provider will test your cancer for an abnormal “*PIK3CA*” gene to make sure that REVTORPYK is right for you.

It is not known if REVTORPYK is safe and effective in children.

Before taking REVTORPYK, tell your healthcare provider about all of your medical conditions, including if you:

- have diabetes.
- are pregnant or plan to become pregnant. REVTORPYK can harm your unborn baby.

Females who are able to become pregnant:

- Your healthcare provider will do a pregnancy test before you start treatment with REVTORPYK.
- Use effective birth control (contraception) during treatment with REVTORPYK and for 2 weeks after the last dose.
- Your healthcare provider will tell you how long you should use birth control (contraception) after your treatment with fulvestrant and palbociclib.
- Talk to your healthcare provider about birth control methods that may be right for you during treatment with REVTORPYK.
- Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with REVTORPYK.

Males with female partners who are able to become pregnant:

- Use effective birth control (contraception) during treatment with REVTORPYK and for 2 weeks after the last dose.
- Tell your healthcare provider right away if your partner becomes pregnant or thinks she may be pregnant during your treatment with REVTORPYK.
- are breastfeeding or plan to breastfeed. It is not known if REVTORPYK passes into breast milk.
 - **Do not** breastfeed during treatment with REVTORPYK and for 2 weeks after the last dose.
 - Your healthcare provider will tell you how long you should not breastfeed after your treatment with fulvestrant and palbociclib.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.

Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.

How will I receive REVTORPYK?

- You will receive REVTORPYK into your vein through an intravenous (IV) line by your healthcare provider.
- REVTORPYK is usually given 1 time every week for 3 weeks followed by 1 week off (28-day treatment cycle).
- You will receive your infusion over 30 minutes.
- Your healthcare provider will decide how many treatments you need.
- Your healthcare provider may slow down or temporarily stop your infusion of REVTORPYK if you have an infusion-related reaction or permanently stop REVTORPYK if you have severe infusion reactions.
- If you miss a planned dose of REVTORPYK, call your healthcare provider right away to schedule an appointment. Do not wait until the next planned treatment cycle.

What are the possible side effects of REVTORPYK?

REVTORPYK can cause serious side effects, including:

- **Mouth sores (stomatitis).** REVTORPYK can cause severe mouth sores, including mouth ulcers. Your healthcare provider will prescribe a steroid-containing mouthwash that is alcohol-free when starting REVTORPYK to help prevent and treat mouth sores. Use the mouthwash as instructed by your healthcare provider. **Do not** eat or drink for at least 1 hour after using the steroid-containing mouthwash. Tell your healthcare provider if you develop any of the following in your mouth:
 - pain
 - swelling
 - redness
 - ulcers
- **Skin reactions.** REVTORPYK can cause skin reactions, including severe rash. You should limit your time in sunlight during treatment with REVTORPYK. Tell your healthcare provider right away if you get a new rash.
- **High blood sugar levels (hyperglycemia).** REVTORPYK can cause severe hyperglycemia. Your healthcare provider will monitor your blood sugar levels before and during treatment with REVTORPYK. It is not known if REVTORPYK is safe in people with Type 1 diabetes or Type 2 diabetes that is not controlled. Tell your healthcare provider right away if you develop signs and symptoms of hyperglycemia, including:

○ excessive thirst ○ more frequent urination than usual or a higher amount of urine than normal ○ blurred vision	○ confusion ○ headache ○ increased appetite with weight loss ○ tiredness
--	---

Your healthcare provider may change your dose, temporarily stop or permanently stop treatment with REVTORPYK if you get serious side effects.

The most common side effects of REVTORPYK when used with fulvestrant and palbociclib include:

- | | |
|--|---|
| <ul style="list-style-type: none"> ○ decreased white blood cell counts ○ decreased red blood cell counts ○ mouth sores ○ nausea ○ decreased platelet counts ○ increased sugar levels (glucose) in the blood ○ tiredness ○ vomiting ○ rash | <ul style="list-style-type: none"> ○ constipation ○ diarrhea ○ increased liver function tests ○ muscle and joint pain ○ decreased sodium levels in the blood ○ increased number of eosinophils (a type of white blood cells) in the blood |
|--|---|

The most common side effects of REVTORPYK when used with fulvestrant include:

- | | |
|---|---|
| <ul style="list-style-type: none"> ○ mouth sores ○ increased sugar levels (glucose) in the blood ○ increased number of eosinophils (a type of white blood cells) in the blood ○ decreased red blood cell counts ○ nausea ○ rash | <ul style="list-style-type: none"> ○ increased liver function tests ○ tiredness ○ muscle and joint pain ○ vomiting ○ itching ○ diarrhea |
|---|---|

REVTORPYK may affect fertility in females and males, which may affect the ability to have children. Talk to your healthcare provider if this is a concern for you.

These are not all of the possible side effects of REVTORPYK.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of REVTORPYK.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information about REVTORPYK that is written for health professionals.

What are the ingredients in REVTORPYK?

Active ingredient: gedatolisib

Inactive ingredients: hydroxypropyl β cyclodextrin and lactic acid and may include hydrochloric acid or sodium hydroxide for pH adjustment.

Manufactured for: Celcuity Inc., 2800 Campus Dr, Suite 140, Minneapolis, MN 55441
 REVTORPYK is a trademark of Celcuity Inc.
 For more information, go to www.celcuity.com or call 1-877-423-5284 (1-877-4-CELCUITY).